Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Zollinger

Neurology Canton, OH Medical Doctor

NPI 1619923133 CMS profile 163658

4048 Dressler Rd Nw Ste 100, Canton, OH 44718

Open in the dashboard

General payments

$3,360

203 records reported · program years 2019–2025

Research payments

$8,157

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,000 paid to institutions, not to them · program year 2023

Through program year 2025, Charles Zollinger of Canton, OH is reported in the CMS Open Payments database as having received $3,360 across 203 general payments and $8,157 in research payments paid to them. Separately, studies naming them as principal investigator received $1,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $527 37
2024 General $415 24
2023 General $570 38
2023 Research $8,098 1
2022 General $581 29
2022 Research $59 1
2021 General $773 49
2020 General $328 19
2019 General $165 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Zollinger
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Charles Zollinger were reported at $527. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Charles Zollinger Neurology median Middle half National median
2019 $165 $474 $118–$2,177 $163
2020 $328 $367 $82–$2,309 $114
2021 $773 $438 $104–$2,547 $132
2022 $581 $442 $103–$2,388 $149
2023 $570 $464 $119–$2,312 $160
2024 $415 $468 $119–$2,323 $164
2025 $527 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,346 99 payments
  2. Alexion Pharmaceuticals, Inc. $298 4 payments
  3. UCB, Inc. $150 6 payments
  4. E.R. Squibb & Sons, L.L.C. $140 8 payments
  5. Novartis Pharmaceuticals Corporation $133 9 payments
  6. SK Life Science, Inc. $116 7 payments
  7. Ge Healthcare $99 8 payments
  8. Genentech USA, Inc. $98 7 payments
  9. Kyowa Kirin, Inc. $91 4 payments
  10. ACADIA Pharmaceuticals Inc $90 5 payments
  11. Other $800 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,260 202 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. QULIPTA $651 51 payments
  2. UBRELVY $612 38 payments
  3. BOTOX $414 39 payments
  4. ULTOMIRIS $193 2 payments
  5. ELIQUIS $140 8 payments
  6. Briviact $114 4 payments
  7. Soliris $104 2 payments
  8. Enspryng $85 6 payments
  9. OCREVUS $80 6 payments
  10. AIMOVIG $80 5 payments
  11. Other $1,228 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $8,157 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

3,840

Median for Neurology: 833

Drug cost

$872,685

Median for Neurology: $202,670

Branded share of claims

29.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 23 $210,610
Aubagio Teriflunomide Brand 12 $110,351
Tysabri Natalizumab Brand 13 $106,251
Avonex Pen (4 Pack) Interferon Beta-1a Brand 13 $105,956
Dimethyl Fumarate Generic 24 $88,031
Nurtec Odt Rimegepant Sulfate Brand 37 $45,595
Aimovig Autoinjector Erenumab-Aooe Brand 46 $33,912
Ubrelvy Ubrogepant Brand 19 $18,891
Emgality Pen Galcanezumab-Gnlm Brand 22 $14,634
Carbidopa-Levodopa Carbidopa/Levodopa Brand 481 $13,426

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$147,194

Of which drugs: $31,303

Medicare patients

751

Average age 73

Services billed

10,737

413 women, 338 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Depression 35%
Ischemic heart disease 31%
Diabetes 29%
Chronic kidney disease 28%
Atrial fibrillation 21%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 39 $36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $112
$112 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $100
$100 — —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $51
$51 — —
QULIPTA
  • AbbVie, Inc. $42
$42 — —
UBRELVY
  • AbbVie, Inc. $41
$41 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record